Menu
Back to User profile » Dr Melissa Toyos
Papers published by Dr Melissa Toyos:
Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial
Schechter BA, Urbieta M, Bacharach J, Toyos M, Smyth-Medina R, Mitchell B, Luchs JI
Clinical Ophthalmology 2022, 16:4145-4151
Published Date: 13 December 2022
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI
Clinical Ophthalmology 2019, 13:215-216
Published Date: 24 January 2019
A Phase II /III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI
Clinical Ophthalmology 2018, 12:2637-2638
Published Date: 14 December 2018
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI
Clinical Ophthalmology 2018, 12:1921-1929
Published Date: 2 October 2018
Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum]
Nichols KK, Holland E, Toyos MM, Peace JH, Majmudar P, Raychaudhuri A, Hamdani M, Roy M, Shojaei A
Clinical Ophthalmology 2018, 12:913-914
Published Date: 17 May 2018
Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
Nichols KK, Holland E, Toyos MM, Peace JH, Majmudar P, Raychaudhuri A, Hamdani M, Roy M, Shojaei A
Clinical Ophthalmology 2018, 12:263-270
Published Date: 31 January 2018